In-vitro studies with ceftazidime.

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Nosocomial infections pose a significant challenge due to multiply-resistant bacteria.
• The emergence of antibiotic resistance necessitates evaluating the efficacy of newer antimicrobial agents.

Purpose of the Study:

• To compare the in vitro activity of ceftazidime against other cephalosporins in treating nosocomial infections.
• To determine the susceptibility patterns of common nosocomial pathogens to ceftazidime.

Main Methods:

• Minimum Inhibitory Concentration (MIC) determinations were performed.
• 275 multiply-resistant nosocomial isolates of enterobacteria and 150 isolates of Pseudomonas aeruginosa were tested.
• Susceptibility testing included ceftazidime, cefotaxime, cefoxitin, cephalothin, ceftriaxone, cefoperazone, moxalactam, cefsulodin, and gentamicin.

Main Results:

• Ceftazidime exhibited greater activity than cefotaxime, cefoxitin, and cephalothin against enterobacteria.
• Enterobacter species showed the highest resistance to ceftazidime (12%), but it remained the most active agent.
• Ceftazidime and cefsulodin were more active than other tested cephalosporins against Pseudomonas aeruginosa.
• Ceftazidime showed less activity against Bacteroides fragilis compared to cefoxitin, but was more active than cefotaxime and cephalothin.

Conclusions:

• Ceftazidime is a highly effective antibiotic against a broad spectrum of multiply-resistant Gram-negative nosocomial pathogens.
• It represents a valuable therapeutic option, particularly for infections caused by Pseudomonas aeruginosa and certain enterobacteria.
• Further clinical evaluation is warranted to confirm its role in managing complex nosocomial infections.